Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549832 | 0.84 | CDK4 (0.50) | CDK4CCND1 | |
| SCHEMBL23016499 | 0.76 | RPS6KA3 (0.48) | CDK4CCND1 | |
| SCHEMBL21014416 | 0.74 | RPS6KA3 (0.44) | CDK4CCND1 | |
| SCHEMBL20926924 | 0.73 | CDK4 (0.53) | CDK4CCND1 | |
| SCHEMBL4549882 | 0.72 | CDK4 (0.34) | CDK4CCND1 | |
| SCHEMBL20392300 | 0.71 | HTR2C (0.49) | CDK4CCND1 | |
| SCHEMBL20926973 | 0.69 | CDK4 (0.80) | CDK4CCND1 | |
| SCHEMBL20913351 | 0.69 | CDK2 (0.43) | CDK4CCND1 | |
| SCHEMBL10082016 | 0.69 | CYP2D6 (0.37) | CDK4CCND1 | |
| SCHEMBL20927005 | 0.67 | CDK4 (0.81) | CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | CDK4 43/4885CCND1 132/4885MET 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.